Gilead (GILD) Rips Following GS-7977 Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $150.43 --0%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: -0.3%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: -0.3%
Join SI Premium – FREE
Gilead Sciences (Nasdaq: GILD) is ripping pre-market Thursday following an update on its proposed treatment for genotype 1 chronic hepatitis C virus (HCV) infection, GS-7977.
According to the release, "the study found that 90 percent of patients (n=47/52, missing data equals failure analysis) achieved a 12-week sustained virologic response (SVR12), defined as maintaining undetectable viral load (HCV RNA <25 IU/mL) 12 weeks after the completion of therapy."
Shares are up over 14 percent early. For more color on the release, click here.
According to the release, "the study found that 90 percent of patients (n=47/52, missing data equals failure analysis) achieved a 12-week sustained virologic response (SVR12), defined as maintaining undetectable viral load (HCV RNA <25 IU/mL) 12 weeks after the completion of therapy."
Shares are up over 14 percent early. For more color on the release, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) PT Raised to $164 at BofA Securities
- Lumentum's optical components sold out through early 2029: CEO
- Gilead Sciences (GILD) PT Raised to $158 at Truist Securities
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
